BidaskClub cut shares of Affimed (NASDAQ:AFMD) from a sell rating to a strong sell rating in a research note published on Tuesday, September 18th.
A number of other research firms have also recently issued reports on AFMD. ValuEngine cut shares of Affimed from a strong-buy rating to a buy rating in a research note on Thursday, September 13th. Jefferies Financial Group upgraded shares of Affimed from a hold rating to a buy rating and boosted their price objective for the stock from $1.80 to $4.00 in a research report on Tuesday, August 28th. BMO Capital Markets boosted their price objective on shares of Affimed from $4.00 to $5.00 and gave the stock an outperform rating in a research report on Tuesday, August 28th. Finally, Zacks Investment Research raised shares of Affimed from a sell rating to a hold rating in a report on Tuesday, June 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $4.81.
AFMD stock traded up $0.07 during trading on Tuesday, reaching $3.38. 583,792 shares of the stock were exchanged, compared to its average volume of 1,101,211. Affimed has a twelve month low of $1.15 and a twelve month high of $7.35. The company has a market cap of $271.40 million, a PE ratio of -4.33 and a beta of 3.57. The company has a quick ratio of 5.33, a current ratio of 5.36 and a debt-to-equity ratio of 0.06.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Affimed by 38.8% in the 2nd quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 49,610 shares in the last quarter. Stanley Laman Group Ltd. bought a new stake in Affimed during the 2nd quarter worth about $100,000. Canada Pension Plan Investment Board bought a new stake in Affimed during the 2nd quarter worth about $165,000. Iguana Healthcare Management LLC bought a new stake in Affimed during the 1st quarter worth about $555,000. Finally, Millennium Management LLC bought a new stake in Affimed during the 1st quarter worth about $4,731,000. 40.63% of the stock is currently owned by institutional investors and hedge funds.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.